ACID AMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

Abstract: The invention relates to new acid amide derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said acid amide derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases. The new compounds according to the invention can be characterized by formula (I), wherein R<1> represents hydrogen or nitro, R<2> and R<3> stand, independently from each other, for hydrogen, lower alkyl or lower alkenyl optionally carrying a substituent selected from the group consisting of halogen, hydroxy, lower alkoxy, di(lower alkyl)amino, phenyl-lower alkoxycarbonyl and a 5- to 6-membered saturated heteroring containing 1 or 2 nitrogen and/or oxygen atom(s); or R<2> and R<3> form, together with the adjacent nitrogen atom, a 6-membered saturated heterocyclic group containing optionally 1 or 2 additional nitrogen atoms and/or oxygen atom(s), said ring optionally carrying a hydroxy or a hydroxy-lower alkyl group, and possess valuable AMPA and kainate antagonizing properties, so they can be used to advantage in the therapy.

Description: ACID AMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF This invention relates to new acid amides, a process for the preparation thereof, pharmaceutical compositions com¬ prising the same, the use of the said compounds for the treatment of diseases and for the preparation of pharmaceuti¬ cal compositions suitable for the treatment of diseases. According to an aspect of the present invention there are provided new acid amides of the formula wherein R 1 represents hydrogen or nitro, R2 and R^ stand, independently from each other, for hydrogen, lower alkyl or lower alkenyl optionally carrying a sub¬ stituent selected from the group consisting of halogen, hydroxy, lower alkoxy, di (lower alkyl)amino, phenyl-lower alkoxycarbonyl and a 5- to 6-membered saturated hetero- ring containing 1 or 2 nitrogen and/or oxygen atom(s); or R2 and R3 form, together with the adjacent nitrogen atom, a 6-membered saturated heterocyclic group containing op¬ tionally 1 or 2 additional nitrogen atoms and/or oxygen atom(s), said ring optionally carrying a hydroxy or a hy¬ droxy-lower alkyl group. The invention encompasses all of the possible mesomers, tautomeric forms and stereoisomers of the acid amides of the formula (I) and the mixtures thereof. The compounds of the formula (I) are AMPA and kainate an¬ tagonists. The term "lower" in respect of the alkyl and alkenyl groups means 1-6 and 2-6 carbon atoms, respectively. The term "alkyl" used throughout the specification and claims refers to straight or branched ones such as methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, n-hexyl etc. Suitably "alkenyl" may include straight or branched ones such as vinyl, allyl, methallyl, butenyl or the like. The term "halogen atom" encompasses all the four halogen atoms, such as fluorine, chlorine, bromine and iodine. As "5- to 6-mem¬ bered heterorings" saturated heterocyclic rings are men¬ tioned, which contain as heteroatom 1 or 2 nitrogen and/or oxygen atom(s) (e.g. pyrrolidinyl, piperidinyl, piperazinyl, pyrazolidinyl, imidazolidinyl, izoxazolidinyl, oxazolidinyl, hexahydropyridazinyl, hexahydropyrimidinyl, tetrahydro-2H- 1, 3-oxazinyl, tetrahydro-lH-1, 2-oxazinyl or morpholinyl) . Preferred representatives of the compounds according to the invention are the following derivatives: 1,2, 3, -tetrahydro-7-nitro-2, 3-dioxo-N- (2-piperidinoethyl) -6- -quinoxaline sulfonamide, N,N-bis (2-hydroxyethyl) -1,2, 3, -tetrahydro-7-nitro-2, 3-dioxo- -6-quinoxaline sulfonamide and pharmaceutically acceptable salts thereof. Those compounds of the formula (I), wherein R2 and R--* stand for basic groups, can form acid addition salts with pharmaceutically acceptable acids (e.g. hydrogen halides, sulfuric acid, maleic acid, fumaric acid, citric acid) . From those compounds of the formula (I), wherein R 2 and R 3 repre¬ sent hydrogen or alkyl, salts can be formed with mineral bases (such as sodium or potassium hydroxide) , whereby the acid amides are converted into salts in form of lactimes. According to a further aspect of the present invention there is provided a process for the preparation of acid am¬ ides of the formula (I), which comprises reacting an acid chloride of the formula wherein R-^ is as stated above, with an amine of the formula wherein R2 and R 3 are as stated above, and optionally converting the thus-obtained compound of the formula (I) into a pharmaceuti¬ cally acceptable salt. The reaction of the acid chlorides of the formula (II) with the amines of the formula (III) is carried out in a po- lar solvent, preferably water or ethanol, at a temperature between -10°C and +100°C, preferably at room temperature. The reaction time varies between 1 hour and 72 hours, preferably between 3 and 8 hours. The product can be isolated from the reaction mixture by a method known per se. If the product separates from the re¬ action mixture in crystalline form, the crystals are filtered off. If the product does not separate from the reaction mix- ture as a consequence of the amine of the formula (III) ap¬ plied in excess, the amine is bound with a mineral or organic acid (e.g. hydrogen chloride or acetic acid) added to the re¬ action mixture in excess, and then the separated product is filtered off. The product can be purified by recrystalliza- tion from an appropriate solvent or by precipitation from a solution formed with a solvent in which the given compound is readily soluble. If the salt formation is carried out with a mineral or organic acid, the compound of the formula (I) is dissolved in an appropriate solvent (e.g. dimethylformamide or dimethyl sulfoxide) , and then the desired acid is added to the solu¬ tion. In those cases wherein a mineral acid has been used for the working up of the reaction mixture, the product separates directly in the form of an acid addition salt. If the salt formation is carried out with a mineral base, the compound of the formula (I) is dissolved e.g. in a di¬ luted (5-10 %) warm solution of sodium or potassium hydr¬ oxide, the obtained solution is cooled and the separated salt is filtered off. The acid chloride of the formula (II), wherein Rl stands for hydrogen, is known from the literature [ Japanese patent specification No. 26,975; Chem. Abstr. 2, 11833 (1965)] . The acid chloride of the formula (II), wherein R-*- stands for nitro, is a new compound. It can be prepared by nitrating an acid chloride of the formula (II), wherein R! represents hydrogen. The compounds of the formula (III) are known from the literature. They are either commercially available or can be prepared by known methods [ Houber-Weyl : "Methoden der Or- ganischen Chemie" , 9th band] . The compounds according to the invention possess valuable AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate antagonizing properties. Among the known quinoxaline dione derivatives CNQX (6-cy- ano-7-nitro-quinoxaline-2, 3-dione) and DNQX (6, 7-dinitro- quinoxaline-2, 3-dione) exhibit selective AMPA antagonizing property [ M.J. Sheardown, E.O. Nielsen, A.J. Hansen, P.Jacobsen, T. Honore: Science 2 7, 571-574, (1990)] . The NMDA (N-methyl-D-aspartate) antagonizing effect of the said compounds is 5 to 30 times weaker than the AMPA antagonizing property thereof [ D.E. Murphy, E.W. Snowhill, M. Williams: Neurochem. Res. Vol. 12., 775-782 (1987)] . The AMPA antago¬ nizing activity is useful in the medicinal prophylaxis of tissue injuries caused by epilepsy, lesions and internal haemorrhages [ S.D. Donovan, M.A. Rogawski: Neuron Vol. 10, 51-59 (1993)] . The compounds having NMDA antagonizing effect can be useful in the therapy due to their anticonvulsive, muscle relaxant and antipsychotic properties . Furthermore they can influence to advantage the neurodegenerative proc¬ esses developing for various reasons [ J. Lehmann: Drugs of the Future, Vol. 1_4, 1059-1071 (1989)] . The compounds accord¬ ing to the invention are both AMPA and NMDA antagonists, so in the course of a therapeutic application they will probably be useful in a wider indication. The activity of the compounds according to the invention is proved by the following tests. As reference the following compounds were applied: DNQX = 6, 7-dinitroquinoxaline-2, 3-dione AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid MK-801 = (+)-5-methyl-10,ll-dihydro-5H-dibenzo[ a,d] cyclo- hepten-5, 10-imine 1 ' CGS-19755 = cis-4-phosphonomethylpiperidine-2-carboxylic acid 2) . 1) (M. Negwer: "Organic Chemical Drugs and their Synony- mes" , compound No. 3906) 21 (EP patent No. 0,203,891) 1. 3-i-AMPA and ^H-kainate binding (radioligand competitive binding assay) The experiment was carried out according to the method of Murphy et al. [ D.E. Murphy, E.W. Snowhill, M. Williams: Neu- rochem. Res. 12, 775-782 (1987)] using a membrane specimen isolated from rat brain. The binding of kainate labeled with tritium on a rat cortex specimen was measured according to the method of Honore et al. [ T. Honore, J. Dejer and M. Niel¬ sen: Neurosci. Lett. 5, 48-52 (1986)] . The inhibition con¬ stants (Ki) are shown in Table I. Table I Compound Binding of 3H-AMPA Binding of (No . of Example) K-L (Mole) 3 H-kainate K- (Mole) 17 6.3 ■10-7 2.0 ■ 10 -6 11 1.4 •10 -6 3.2 ■ 10 -6 12 2.0 10 -5 1.0 10 "3 24 2.1 >10 -6 2.4 10 "5 23 8.6 10 -6 4.2 10-4 13 1.0 10 -5 6.7 10 -6 19 4.4 10 -6 3.8 10 "6 14 1.6 10 -6 1.5 10 -5 26 1.6 10 -6 1.7 10 "3 16 1.3 10 -5 1.6- 10 -5 15 8.2 10 "6 1.5- 10 -5 DNQX 8.8 10-7 2.0- 10 -6 AMPA 1.4 10-8 - Kainate - 2.2- 10-8 From the data of the above Table I it can be established that the most active compound, the compound of Example 17, displaced labeled kainate and AMPA with an affinity similar to that of DNQX. Thus, the said molecule is a good reversible ligand for both the AMPA and kainate recognition site. 2. Selectivity The experiment was carried out according to the method of Foster et al. [A.Foster and E.H.F. Wong: Brit. J. Pharmacol. ]_, 403-409, (1987)] . When applying the CGS 19755 receptor binding test the method of Murphy et al. [ D.E. Murphy, A.J. Hutchison, S.D. Hurt, M. Williams and M.A. Sills: Brit. J. Pharmacol. 95_, 932-938 (1988)] was applied. The data are shown in Table II. Table II Compound (No . Binding of -^H-MK- Binding of J H-CGS-19755 K of Example) 801K - (Mole/1 ) (Mole/1 ) 17 3.9 10 -3 non-linear regression does not "converge" 24 2.8 10 "3 non-linear regression does not "converge" DNQX 8.9 10 -6 non-linear regression does not "converge" From the above Table II it can be established that the examined compounds are weak displacers of MK-801, but failed to displace at all the reversible NMDA antagonist tracer CGS- 19755. Therefore the compounds of Examples 17 and 24 are se¬ lective AMPA and kainate antagonists, and as it is to be ex¬ pected, they will be useful in the treatment of diseases con¬ nected with glutamatergic neurontransmission (ischemia, cere- bral and spinal injuries, hypoglycemia, chronic neurodegen- erative diseases) . According to a further aspect of the present invention there are provided pharmaceutical compositions comprising as active ingredient a compound of the formula (I) or a pharma¬ ceutically acceptable salt thereof in admixture with suitable inert solid or liquid pharmaceutical carriers. The pharmaceutical compositions of the present invention can be prepared by methods known per se by admixing the active ingredient with suitable inert, non-toxic, solid or liquid carriers and bringing the mixture to galenic form. It is preferred to finish the compounds of the formula (I) to tablets or dragees, but they can be administered in form of solution or suspension, too. The daily oral dose is generally 10 to 1000 mg, preferably 100 to 600 mg for an adult human being of about 70 kg. According to a further aspect of the present invention there is provided the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for the prepara- tion of pharmaceutical compositions having particularly AMPA and kainate antagonizing properties. According to a still further aspect of the present inven¬ tion there is provided a method of AMPA and kainate antago¬ nizing treatment, which comprises administering to a patient an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof. Further details of the present invention are to be found in the following Examples without limiting the scope of pro¬ tection to the said Examples. Example 1 1 ,2 , 3 , -Tetrahydro-2 , 3-dioxo-6-quinoxaline sulfonamide and its disodium salt A suspension of 5.21 g (0.02 mole) of 1, 2, 3, 4-tetrahydro- 2, 3-dioxo-6-quinoxalinesulfonyl chloride and 40 ml of 25 % ammonium hydroxide is stirred at room temperature for 6 hours. Then it is filtered, the separated material is washed with water and acetone, filtered, dried, dissolved in a slight amount of hot dimethyl sulfoxide, and the product is precipit ed from the solution by adding a slight amount of 2-propanol to it. Thus 0.70 g (15 %) of 1,2, 3, 4-tetrahydro- 2, 3-dioxo-6-quinoxaline sulfonamide is obtained, m.p.: >360 °C. 0.70 g of the above compound are dissolved in 10 ml of a hot 10% aqueous sodium hydroxide solution. On cooling the de¬ sired disodium salt separates, m.p. is higher than 350°C. Example 2 N,N-Dimethyl- 1 ,2, 3, 4 -tetrahydro-2 , 3-dioxo-6-quinoxaline sulfonamide A mixture of 3.91 g (0.015 mole) of 1, 2, 3, 4-tetrahydro- 2, 3-dioxo-6-quinoxalinesulfonyl chloride and 30 ml of 25 % aqueous dimethylamine is stirred at room temperature for 6 hours. Then it is filtered, the separated crystals are washed successively with water and acetone, filtered, dried and re- crystallized from water. Thus 1.40 g (35 %) of N,N-dimethyl- 1, 2, 3, 4-tetrahydro-2, 3-dioxo-6-quinoxaline sulfonamide is ob¬ tained, m.p.: 258-266 °C. Example 3 N- (2-Bromoethyl) -1, 2, 3 , 4 -tetrahydro-2 , 3-dioxo-6-quinoxa- line sulfonamide 20.49 g (0.1 mole) of 2-bromoethylamine hydrobromide and 4.00 g (0.1 mole) of sodium hydroxide are dissolved in 60 ml of water, and 7.82 g (0.03 mole) of 1,2, 3,4-tetrahydro-2,3- dioxo-6-quinoxalinesulfonyl chloride are added to the solu¬ tion, and the mixture is stirred at room temperature for 6 hours. Then it is allowed to stand for 16 hours. The sepa- rated crystals are filtered, washed successively with water and acetone, dried, dissolved in a slight amount of hot dime¬ thyl sulfoxide and precipitated from the solution with water. Thus 3.44 g (33 %) of N-(2-bromoethyl)-1,2,3,4-tetrahydro- 2,3-dioxo-6-quinoxaline sulfonamide are obtained, m.p.: 261- 266 β C. Example 4 N,N-bis- (2 -hydroxy ethyl) -1 , 2 , 3 , 4 -tetrahydro-2, 3-dioxo-6- quinoxaline sulfonamide To a solution of 10.51 g (0.1 mole) of diethanolamine in 40 ml of water 5.21 g (0.02 mole) of 1,2,3,4-tetrahydro-2,3- dioxo-6-quinoxalinesulfonyl chloride are added in small por¬ tions, under stirring. The mixture is stirred at room tem¬ perature for 10 hours and allowed to stand for 16 hours. The separated crystals are filtered, washed successively with wa- ter and acetone, dried, dissolved in a slight amount of hot dimethyl sulfoxide and precipitated from the solution with water. Thus 3.37 g (51 %) of N.N-bis-(2-hydroxyethyl)- 1,2,3,4-tetrahydro-2,3-dioxo-6-quinoxaline sulfonamide are obtained, m.p.: 272-276°C. According to the method of Example 4 the following acid amides were prepared: Example 5 J - (1 , 2, 3, 4-Tetrahydro-2, 3-dioxo-6-quinoxalinesulfonyl)pi- peridine M . p . : >335 °C . Yield : 79 % . Example 6 4- (1 ,2, 3, 4 -Tetrahydro-2 , 3-dioxo-6-quinoxalinesulfonyl)- morpholine M.p.: >330 β C. Yield : 66 %. Example 7 N- (Benzyloxycarbonyl ethyl ) -1 , 2, 3 , 4 -tetrahydro-2 , 3-dioxo- 6-quinoxaline sulfonamide To a solution of 4.14 g (0.03 mole) of potassium carbonate in 25 ml of .water 10.12 g (0.03 mole) of aminoacetic acid benzyl ester tosylate are added in small portions, under stirring. Then 5.21 g (0.02 mole) of 1,2,3,4- tetrahydro-2,3-dioxo-6-quinoxalinesulfonyl chloride are added to the mixture, it is stirred at room temperature for 6 hours and allowed to stand for 16 hours. The separated crystals are filtered off, washed with water and acetone, dried, dissolved in a slight amount of hot dimethyl sulfoxide and precipitated with water. Thus 3.50 g (45 %) of N-(benzyl-oxycarbonyl- methyl)-1, 2 , 3, -tetrahydro-2,3-dioxo-6-quinoxaline sulfon¬ amide are obtained. M.p.: 270-280°C. Example 8 N- (n-Butyl) -1 , 2 , 3 , 4-tetrahydro-2 , 3-dioxo-6-quinoxaline sulfonamide To a solution of 7.31 g (0.1 mole) of n-butylamine in 20 ml of water 5.21 g (0.02 mole) of 1,2,3,4-tetrahydro-2,3- dioxo-6-quinoxalinesulfonyl chloride are added, and the mix- ture is stirred at room temperature for 5 hours. Then it is allowed to stand for 16 hours, the separated crystals are filtered off, washed with water, dried and recrystallized from acetone. Thus 4.50 g (76 %) of N-(n-butyl)-1,2,3,4-tet- rahydro-2,3-dioxo-6-quinoxaline sulfonamide are obtained, m.p. : 257-262°C. Example 9 1 , 2 , 3 , 4 -Tetrahydro-N- (2-methoxyethyl) -2 , 3-dioxo-6-qui- noxaline sulfonamide To a solution of 7.51 g (0.1 mole) of 2-methoxyethylamine in 20 ml of water 5.21 g (0.02 mole) of 1,2,3,4-tetrahydro- 2,3-dioxo-6-quinoxalinesulfonyl chloride are added in small portions, under stirring, and the mixture is stirred at room temperature for 16 hours. It is allowed to stand further for 2 days, and then 15 ml of acetic acid and 10 ml of water are added to it. The separated crystals are filtered, washed suc¬ cessively with water and acetone, dried, dissolved in a slight amount of hot dimethyl sulfoxide and precipitated from the solution with water. Thus 3.80 g (63 %) of 1,2,3,4-tetra- hydro-N-(2-methoxy-ethyl)-2,3-dioxo-6-quinoxaline sulfonamide are obtained, m.p.: 264-267 β C. Example 10 1 , 2 , 3 , 4-Tetrahydro-l -nitro-2 , 3-dioxo-S-quinoxaline sul¬ fonamide A mixture of 4.58 g (0.015 mole) of 1, 2 ,3,4-tetrahydro-7- nitro-2, 3-dioxo-6-quinoxalinesulfonyl chloride and 30 ml of 25 % ammonium hydroxyde is stirred at a temperature between 5°C and 10 β C for 3 hours and then allowed to stand for 16 hours. To the mixture 6 ml of acetic acid and 40 ml of water are added, the separated crystals are filtered off, washed with water and acetone, dried and dissolved in a slight amount of hot dimethyl sulfoxide. The product is precipitated from this solution with 2-propanol. Thus 1.40 g (17%) of 1,2,3,4-tetrahydro-7-nitro-2, 3-dioxo-6-quinoxaline sulfon¬ amide are obtained, m.p.: >330°C. Example 11 N,N-Dimethyl-1 , 2 , 3 , 4-tetrahydro-l -nitro-2 , 3-dioxo-6-qui- noxaline sulfonamide A mixture of 4.58 g (0.015 mole) of 1,2,3,4-tetrahydro-7- nitro-2,3-dioxo-6-quinoxalinesulfonyl chloride and 30 ml of 25 % ethanolic dimethylamine is stirred at a temperature between 5 °C and 10 C C for 3 hours, and then allowed to stand for 16 hours. To the reaction mixture 5 ml of acetic acid and 60 ml of water are added, the separated crystals are fil- tered, washed with water and acetone, dried, dissolved in a slight amount of hot dimethyl sulfoxide and precipitated from this solution with water. Thus 3.80 g (81 %) of N,N-dimethyl- 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-6-quinoxaline sulfon¬ amide are obtained, m.p. : 318-332 β C. Example 12 N,N-Diethyl-1 , 2 , 3 , 4-tetrahydro-l -nitro-2 , 3-dioxo-β-qui- noxaline sulfonamide To a solution of 10.97 g (0.015 mole) of diethylamine in 20 ml of acetone 4.58 g (0.015 mole) of 1,2,3,4-tetrahydro-7- nitro-2, 3-dioxo-6-quinoxalinesulfonyl chloride are added at a temperature between 5 °C and 10 °C, under stirring, the mix¬ ture is stirred at the same temperature for 3 hours and al¬ lowed to stand for 16 hours. Then 6 ml of acetic acid and 40 ml of water are added to the mixture, the separated crystals are filtered off, washed with water and acetone, dried and recrystallized from acetonitrile. Thus 3.50 g (59 %) of N,N- diethyl-1,2,3, 4-tetrahydro-7-nitro-2,3-dioxo-6-quinoxaline sulfonamide are obtained, m.p.: >360°C. Example 13 1 , 2 , 3 , 4-Tetrahydro-N- (2-methoxyethyl) -l-nitro-2 , 3-dioxo- 6-quinoxaline sulfonamide To a solution of 3.76 g (0.05 mole) of 2-methoxyethyl- amine in 15 ml of water 6.11 g (0.02 mole) of 1,2,3,4-tetra- hydro-7-nitro-2,3-dioxo-6-quinoxalinesulfonyl chloride are added at room temperature, under stirring. The mixture is stirred at room temperature for 6 hours and then allowed to stand for 16 hours. The separated crystals are filtered off, washed successively with water and acetone, filtered again, dried and dissolved in a slight amount of hot dimethyl sulf¬ oxide. The product is precipitated from this solution with water. Thus 4.05 g (59 %) of 1,2,3,4-tetrahydro-N-(2-methoxy- -ethyl)-7-nitro-2,3-dioxo-6-quinoxaline sulfonamide are ob¬ tained, m.p.: 320-321°C. According to the method of Example 13 the following acid amides of the formula (I) were prepared: Example 14 N- (3-Dimethylaminopropyl) -1 , 2 , 3 , 4-tetrahydro-l -nitro-2 , 3- dioxo-6-quinoxaline sulfonamide M.p.: 195-206°C. Yield: 84 %. In order to prepare the corresponding hydrochloride salt, the thus-obtained compound is dissolved in dimethyl form- amide, a 10% solution of hydrochloric acid in isopropanol is added, the separated crystals are filtered off and washed with isopropanol. The melting point of the crystals is higher than 340°C. Example 15 1 - ( 1 , 2, 3 , 4-Tetrahydro-l -nitro-2 , 3-dioxo-6-quinoxaline- -sulfonyl) -4-hydroxypiperidine M.p.: 310-315°C. Yield: 45 %. Example 16 1- (2 -Hydroxy ethyl) -4- (1 , 2 , 3 , 4-tetrahydro-l -nitro-2 , 3- -dioxo-6-quinoxalinesulfonyl) -piperazine M.p.: 273-275°C. Yield: 54 %. - 15 - Example 17 1 , 2 , 3 , 4 -Tetrahydro-1 -nitro-2 , 3-dioxo-N- (2-piperidino¬ ethyl) -6-quinoxaline sulfonamide M.p.: 272-280°C. Yield: 82 %. Exarple 18 N,N-Diallyl-1, 2 , 3 , 4-tetrahydro-l -nitro-2 , 3-dioxo- 6-qui¬ noxaline sulfonamide M.p.: >360°C. Yield: 90 %. Example 19 N-Allyl-1 , 2 , 3 , 4-tetrahydro-l -nitro-2 , 3-dioxo-6-quinoxa- line sulfonamide M.p.: 260-265°C. Yield: 31 %. Example 20 1 ,2, 3, 4-Tetrahydro-N- [3- (4-morpholino) -propyl] -1-nitro- -2 ,3-dioxo-6-quinoxaline sulfonamide M.p . : 256-262 °C . Yield : 17 % . Example 21 1 , 2 , 3 , 4-Tetrahydro-N- [2- (4-morpholino) -ethyl] -1-nitro- -2 , 3-dioxo- 6-quinoxaline sulfonamide M. p . : 283-291 °C . Yield : 18 % . Example 22 1 , 2 , 3 , 4-Tetrahydro-N- [2- (1 -pyrrolidinoethyl) ] -1-nitro- -2 , 3-dioxo- 6-quinoxaline sulfonamide M.p.: 268-277°C. Yield: 56 %. Example 23 N- (n-Butyl) -N- (2-hydroxyethyl) -1 , 2 , 3 , 4 -tetrahydro-1- -nitro-2 , 3-dioxo-6-quinoxaline sulfonamide M.p.: 295-316°C. Yield: 15 %. Example 24 N,N-bis (2-Hydroxyethyl) -1 , 2 , 3 , 4-tetrahydro-l -nitro-2 , 3- dioxo- 6-quinoxaline sulfonamide To a solution of 10,5 g (0.1 mole) of diethanolamine in 40 ml of water 6.11 g (0.02 mole) of 1,2,3, -tetrahydro-7- -nitro-2,3-dioxo-6-quinoxalinesulfonyl chloride are added un¬ der stirring, the reaction mixture is stirred at room tem¬ perature for 6 hours and then allowed to stand for 16 hours. The separated crystals are filtered off, washed with water, dried and recrystallized from acetone. Thus 3.90 g (52 %) of N,N-bis (2-hydroxyethyl)-1,2,3,4-tetrahydro-7-nitro-2,3-dioxo- 6-quinoxaline sulfonamide are obtained, m.p.: 310-321°C. Example 25 1 , 2 , 3 , 4-Tetrahydro-N- (2-hydroxyethyl)-7 '-nitro-2 , 3-dioxo - 6-quinoxaline sulfonamide To a solution of 6.11 g (0.1 mole) of ethanolamine in 40 ml of water 6.11 g (0.02 mole) of 1,2, 3, -tetrahydro-7-nitro- 2,3-dioxo-6-quinoxalinesulfonyl chloride are added under stirring, the reaction mixture is stirred at room temperature for 6 hours and then allowed to stand for 16 hours. The sepa¬ rated crystals are filtered off, washed with acetone, dried, dissolved in a slight amount of hot dimethyl sulfoxide and precipitated from this solution with 2-propanol. Thus 3.70 g (56 %) of 1,2,3,4-tetrahydro-N-(2-hydroxyethyl)-7-nitro-2, 3- dioxo-6-quinoxaline sulfonamide are obtained, m.p.: 281- 289°C. Example 26 1 - (1 , 2, 3, -Tetrahydro-l -nitro-2 , 3-dioxo-6-quinoxaline- -sulfonyl) - orpholine To a solution of 8.72 ' g (0.1 mole) of morpholine in 80 ml of water 6.11 g (0.02 mole) of 1,2, 3, 4-tetrahydro-7-nitro- 2,3-dioxo-6-quinoxalinesulfonyl chloride are added under stirring, the reaction mixture is stirred at room temperature for 6 hours and then allowed to stand for 16 hours. The sepa¬ rated crystals are filtered off, washed with water, dried, dissolved in a slight amount of hot dimethyl sulfoxide and precipitated from this solution with water. Thus 5.76 g (81%) 1-(1,2,3, -tetrahydro-7-nitro-2,3-dioxo-6-quinoxaline- sulfonyl)-morpholine are obtained, m.p.: >360°C.

Claims: What we claim is: 1. Acid amides of the formula wherein Rl represents hydrogen or nitro, R 2 and R 3 stand, independently from each other, for hydrogen, lower alkyl or lower alkenyl optionally carrying a sub¬ stituent selected from the group consisting of halogen, hydroxy, lower alkoxy, di (lower alkyl) amino, phenyl-lower alkoxycarbonyl and a 5- to 6-membered saturated hetero- ring containing 1 or 2 nitrogen and/or oxygen atom(s); or R2 and R 3 form, together with the adjacent nitrogen atom, a 6-membered saturated heterocyclic group containing optionally 1 or 2 additional nitrogen atoms and/or oxygen atom(s), said ring optionally carrying a hydroxy or a hydroxy-lower alkyl group, and pharmaceutically acceptable salts thereof. 2. 1,2,3, 4-Tetrahydro-7-nitro-2, 3-dioxo-N- (2-piperidino- ethyl) -6-quinoxaline sulfonamide, N,N-bis (2-hydroxyethyl) -1,2,3, 4-tetrahydro-7-nitro-2, 3- dioxo-6-quinoxaline sulfonamide, and pharmaceutically acceptable salts thereof. 3. A process for the preparation of acid amides of the formula and pharmaceutically acceptable salts thereof, which com¬ prises reacting an acid chloride of the formula wherein R* is as stated above, with an amine of the formula wherein R 2 and R 3 are as stated above, and, if desired, con¬ verting the thus-obtained compound of the formula (I) into a pharmaceutically acceptable salt. 4. A process as claimed in claim 3, which comprises car¬ rying out the reaction in a polar solvent. 5. Pharmaceutical compositions comprising as active in¬ gredient a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof in admixture with suitable inert solid or liquid pharmaceuti¬ cal carriers. 6. A process for the preparation of pharmaceutical compo¬ sitions according to claim 5, which comprises admixing a com¬ pound of the formula (I) or a pharmaceutically acceptable salt thereof with suitable inert solid or liquid therapeu- tical carriers. 7. Use of compounds of the formula (I) or pharmaceuti¬ cally acceptable acid addition salts thereof for the prepara¬ tion of pharmaceutical compositions having AMPA and kainate antagonizing properties. 8. Method of AMPA and kainate antagonizing treatment, which comprises administering to a patient a therapeutically effective amount of a compound of the formula (I) or a phar¬ maceutically acceptable salt thereof.

Inventors: BLASKO GABOR, FEKETE MARTON, GAAL LASZLO, MAKARA GABOR, REITER JOZSEF, RIVO ENDRE, SIMIG GYULA, VIZI E SZILVESZTER, BLASKO, GABOR, FEKETE, MARTON, GAAL, LASZLO, MAKARA, GABOR, REITER, JOZSEF, RIVO, ENDRE, SIMIG, GYULA, VIZI, E., SZILVESZTER
Applicants: BLASKO GABOR, EGYT GYOGYSZERVEGYESZETI GYAR, FEKETE MARTON, GAAL LASZLO, MAKARA GABOR, REITER JOZSEF, RIVO ENDRE, SIMIG GYULA, VIZI E SZILVESZTER, BLASKO, GABOR, EGIS GYOGYSZERGYAR RT., FEKETE, MARTON, GAAL, LASZLO, MAKARA, GABOR, REITER, JOZSEF, RIVO, ENDRE, SIMIG, GYULA, VIZI, E., SZILVESZTER
Application year: 1995
Main classification: C07D241
IPC codes: A61K31, A61P21, A61P25, C07D241, C07D413